BOSTON, Massachusetts — December 16, 2025 — Leads & Copy — Galecto, Inc. (Nasdaq: GLTO) announced that its Board of Directors has approved a non-qualified stock option grant for a new employee. The grant, approved on December 15, 2025, involves 312,535 shares of the company’s common stock.
The “Inducement Grant” was made under the company’s 2022 Inducement Plan, as amended. It was designed to encourage the individual to accept employment with the company, in compliance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant’s exercise price is $32.00 per share. The shares will vest 25% on the first anniversary of the Grant Date, and then an additional 1/48th each month after that, conditional on the employee’s continued employment.
Galecto, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for hematological cancers. Its pipeline features treatments for essential thrombocythemia and myelofibrosis, targeting mutant calreticulin (mut-CALR). Galecto anticipates submitting an IND or equivalent filing for DMR-001, a monoclonal antibody targeting mutCALR, in mid-2026. The pipeline also includes GB3226, a dual inhibitor of ENL-YEATS and FLT3 for AML treatment.
Lia Dangelico, Deerfield Group, lia.dangelico@deerfieldgroup.com
Sandya von der Weid, LifeSci, svonderweid@lifesciadvisors.com
Source: Galecto, Inc.
